PharmaCyte BiotechPMCB -0.30%32 Pretax Margin % is % as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, PharmaCyte Biotech ranks worse than 105708.14% on this metric.
The historical rank and industry rank for PharmaCyte Biotech's Pretax Margin % or its related term are showing as below:
PMCB's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.5 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
PharmaCyte Biotech Pretax Margin % Related Terms
PharmaCyte Biotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMCB vs IMNN, ACXP, ENVB: Pretax Margin % Comparison
For the Biotechnology subindustry, PharmaCyte Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (PMCB) has a Pretax Margin % of % as of Jan. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #999999 out of 946 companies in the Biotechnology industry.
Is PharmaCyte Biotech's Pretax Margin % too high?
PharmaCyte Biotech's current Pretax Margin % is %. Based on the distribution chart, PharmaCyte Biotech ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Pretax Margin % compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #999999 out of 946 companies for Pretax Margin %. This places PharmaCyte Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Pretax Margin % of %. The current Pretax Margin % is %. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Pretax Margin % is % as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score
Get the complete analysis for PMCB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
